Lss-11

Lss-11 (0.5-2 μM; 72 h) has an IC₅₀ of 6.87 μM in Paclitaxel (HY-B0015)-resistant A549/T lung cancer cells and >10 μM in Paclitaxel-sensitive A549 lung cancer cells, and synergizes with Paclitaxel to reduce A549/T cell viability^[1].
Lss-11 (0.5 μM; 6-24 h) increases the percentage of apoptotic Paclitaxel-resistant A549/T lung cancer cells in a time-dependent manner, reaching 16.50% after 24 h of treatment^[1].
Lss-11 (0.5-2 μM; 24 h) increases DR5 and cleaved PARP1 protein levels without altering Bax or Bcl2 levels, and reduces MRP1 protein levels, in Paclitaxel-resistant A549/T lung cancer cells^[1].
Lss-11 (0.5-2 μM; 24 h) reduces phosphorylated STAT3 protein levels while increasing total STAT3 protein levels in Paclitaxel-resistant A549/T lung cancer cells, with p-STAT3 reduction strongly correlated with MDR1 and MRP1 downregulation^[1].
Lss-11 (0.5-2 μM; 24 h) significantly downregulates MDR1 and MRP1 mRNA levels in Paclitaxel-resistant A549/T lung cancer cells^[1].
Lss-11 (0.5-2 μM; 24 h) reduces P-gp protein expression in Paclitaxel-resistant A549/T lung cancer cells^[1].
Lss-11 (24 h) hinders the binding of STAT3 to the MDR1 and MRP1 promoters in paclitaxel-resistant A549/T lung cancer cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.